eszopiclone + eszopiclone + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Generalized Anxiety Disorder
Conditions
Generalized Anxiety Disorder
Trial Timeline
Jan 1, 2008 → Dec 1, 2008
NCT ID
NCT00616655About eszopiclone + eszopiclone + Placebo
eszopiclone + eszopiclone + Placebo is a phase 2 stage product being developed by Sumitomo Pharma for Generalized Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00616655. Target conditions include Generalized Anxiety Disorder.
What happened to similar drugs?
12 of 20 similar drugs in Generalized Anxiety Disorder were approved
Approved (12) Terminated (3) Active (7)
✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00856973 | Phase 3 | Completed |
| NCT00616655 | Phase 2 | Completed |
Competing Products
20 competing products in Generalized Anxiety Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 38 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 32 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 40 |
| zonisamide | Eisai | Pre-clinical | 26 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Perampanel | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Cenobamate | Ono Pharmaceutical | Phase 3 | 47 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 40 |
| Duloxetine + Placebo | Eli Lilly | Approved | 43 |
| Ixekizumab | Eli Lilly | Approved | 43 |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment | Sumitomo Pharma | Approved | 43 |
| ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) | AbbVie | Phase 2 | 42 |
| Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day | AbbVie | Phase 2 | 27 |
| ABBV-932 + Placebo | AbbVie | Phase 1 | 29 |
| Escitalopram | AbbVie | Approved | 43 |
| Adalimumab | AbbVie | Phase 3 | 40 |
| Quetiapine fumarate + Paroxetine | AstraZeneca | Phase 3 | 40 |